Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.

de Vries, M K; Brouwer, E; van der Horst-Bruinsma, I E; Spoorenberg, A; van Denderen, J C; Jamnitski, A; Nurmohamed, M T; Dijkmans, B A C; Aarden, L A; Wolbink, G J

de Vries, M K; Brouwer, E; van der Horst-Bruinsma, I E; Spoorenberg, A; van Denderen, J C; Jamnitski, A; Nurmohamed, M T; Dijkmans, B A C; Aarden, L A; Wolbink, G J.

Ann Rheum Dis ; 68(11): 1787-8, 2009 Nov.

Article in En | MEDLINE | ID: mdl-19822712

Subject(s)

Antibodies, Anti-Idiotypic/biosynthesis; Antibodies, Monoclonal/immunology; Antirheumatic Agents/immunology; Spondylitis, Ankylosing/immunology; Adalimumab; Adult; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Antirheumatic Agents/therapeutic use; Drug Tolerance; Female; Humans; Male; Middle Aged; Spondylitis, Ankylosing/drug therapy; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spondylitis, Ankylosing / Antibodies, Anti-Idiotypic / Antirheumatic Agents / Antibodies, Monoclonal Type of study: Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Ann Rheum Dis Year: 2009 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google